Monopar Therapeutics 在股票发行中筹集了 1 亿美元，用于资助研发。 Monopar Therapeutics raised $100 million in a stock offering to fund research and development.

Monopar Therapeutics 对 1.35 亿美元的普通股和预融资认股权证的承销发行进行了定价，在从 Tactic Pharma 回购 3500 万美元股票后，预计收益将净收益约 1 亿美元。 Monopar Therapeutics priced a $135 million underwritten offering of common stock and pre-funded warrants, with proceeds expected to net about $100 million after a $35 million stock repurchase from Tactic Pharma. 该公司计划利用资金用于研究、临床试验、制造和周转资本。 The company plans to use funds for research, clinical trials, manufacturing, and working capital. 由Morgan Stanley、Leerink Partners和Barclays管理的这项提议定于2025年9月25日结束,并且是向证交会提交的交存登记的一部分。 The offering, managed by Morgan Stanley, Leerink Partners, and Barclays, is set to close on September 25, 2025, and is part of a shelf registration filed with the SEC. 这些证券是根据SEC网站上提供的一份计划书补充书提供的。 The securities are being offered under a prospectus supplement available on the SEC’s website. 莫诺帕正在开发威尔逊病和晚期癌症的治疗方法. Monopar is developing treatments for Wilson disease and advanced cancers. 前瞻性声明涉及与监管和市场因素相关的风险。 Forward-looking statements involve risks related to regulatory and market factors.